Viewing StudyNCT06479135

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-07-17 @ 11:04 AM
Last Modification Date: 2024-10-26 @ 3:33 PM
Study NCT ID: NCT06479135
Status: RECRUITING
Last Update Posted: 2024-06-28
First Post: 2024-06-21
Brief Title: Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Sponsor: Kartos Therapeutics Inc
Organization: Kartos Therapeutics Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Myelofibrosis
Post-PV MF
Post-ET Myelofibrosis
Primary Myelofibrosis
MF
Keywords:
Name View
Navtemadlin View
KRT-232 View
Ruxolitinib View
POIESIS View
TP53 View
Suboptimal response View
Sub-optimal response View